Logo image of AKBA

AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis

NASDAQ:AKBA - Nasdaq - US00972D1054 - Common Stock - Currency: USD

2.83  +0.02 (+0.71%)

Premarket: 2.84 +0.01 (+0.35%)

Fundamental Rating

2

Taking everything into account, AKBA scores 2 out of 10 in our fundamental rating. AKBA was compared to 561 industry peers in the Biotechnology industry. AKBA may be in some trouble as it scores bad on both profitability and health. AKBA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AKBA has reported negative net income.
In the past year AKBA has reported a negative cash flow from operations.
In the past 5 years AKBA always reported negative net income.
In the past 5 years AKBA always reported negative operating cash flow.
AKBA Yearly Net Income VS EBIT VS OCF VS FCFAKBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -14.61%, AKBA belongs to the top of the industry, outperforming 81.46% of the companies in the same industry.
AKBA's Return On Equity of -184.34% is on the low side compared to the rest of the industry. AKBA is outperformed by 66.49% of its industry peers.
Industry RankSector Rank
ROA -14.61%
ROE -184.34%
ROIC N/A
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKBA Yearly ROA, ROE, ROICAKBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

AKBA has a better Gross Margin (82.92%) than 86.10% of its industry peers.
AKBA's Gross Margin has improved in the last couple of years.
AKBA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
AKBA Yearly Profit, Operating, Gross MarginsAKBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

2

2. Health

2.1 Basic Checks

AKBA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKBA has more shares outstanding
Compared to 5 years ago, AKBA has more shares outstanding
Compared to 1 year ago, AKBA has a worse debt to assets ratio.
AKBA Yearly Shares OutstandingAKBA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AKBA Yearly Total Debt VS Total AssetsAKBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

AKBA has an Altman-Z score of -5.15. This is a bad value and indicates that AKBA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.15, AKBA is not doing good in the industry: 62.03% of the companies in the same industry are doing better.
AKBA has a Debt/Equity ratio of 1.89. This is a high value indicating a heavy dependency on external financing.
AKBA's Debt to Equity ratio of 1.89 is on the low side compared to the rest of the industry. AKBA is outperformed by 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF N/A
Altman-Z -5.15
ROIC/WACCN/A
WACC10.3%
AKBA Yearly LT Debt VS Equity VS FCFAKBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

AKBA has a Current Ratio of 2.23. This indicates that AKBA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.23, AKBA is doing worse than 73.08% of the companies in the same industry.
AKBA has a Quick Ratio of 2.02. This indicates that AKBA is financially healthy and has no problem in meeting its short term obligations.
AKBA has a Quick ratio of 2.02. This is in the lower half of the industry: AKBA underperforms 73.62% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.02
AKBA Yearly Current Assets VS Current LiabilitesAKBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.70% over the past year.
AKBA shows a decrease in Revenue. In the last year, the revenue decreased by -1.23%.
The Revenue for AKBA have been decreasing by -13.72% on average. This is quite bad
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
Revenue 1Y (TTM)-1.23%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%75.84%

3.2 Future

AKBA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.37% yearly.
Based on estimates for the next years, AKBA will show a very strong growth in Revenue. The Revenue will grow by 35.60% on average per year.
EPS Next Y48.07%
EPS Next 2Y41.42%
EPS Next 3Y36.46%
EPS Next 5Y52.37%
Revenue Next Year26.41%
Revenue Next 2Y36.64%
Revenue Next 3Y32.75%
Revenue Next 5Y35.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 0 2 -2 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

AKBA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKBA Price Earnings VS Forward Price EarningsAKBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AKBA is valued cheaply inside the industry as 91.80% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 65.95
AKBA Per share dataAKBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as AKBA's earnings are expected to grow with 36.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y36.46%

More info and screens

0

5. Dividend

5.1 Amount

AKBA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (5/22/2025, 8:00:00 PM)

Premarket: 2.84 +0.01 (+0.35%)

2.83

+0.02 (+0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners28.67%
Inst Owner Change49.46%
Ins Owners2.6%
Ins Owner Change7.7%
Market Cap740.84M
Analysts86
Price Target7.52 (165.72%)
Short Float %7.2%
Short Ratio3.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)71.41%
Min EPS beat(2)-22.55%
Max EPS beat(2)165.36%
EPS beat(4)2
Avg EPS beat(4)28.62%
Min EPS beat(4)-54.81%
Max EPS beat(4)165.36%
EPS beat(8)4
Avg EPS beat(8)8.98%
EPS beat(12)7
Avg EPS beat(12)20.67%
EPS beat(16)7
Avg EPS beat(16)9.15%
Revenue beat(2)2
Avg Revenue beat(2)23.65%
Min Revenue beat(2)22.05%
Max Revenue beat(2)25.24%
Revenue beat(4)2
Avg Revenue beat(4)4.07%
Min Revenue beat(4)-17.55%
Max Revenue beat(4)25.24%
Revenue beat(8)2
Avg Revenue beat(8)-4.48%
Revenue beat(12)5
Avg Revenue beat(12)9.4%
Revenue beat(16)7
Avg Revenue beat(16)9.7%
PT rev (1m)0%
PT rev (3m)2.91%
EPS NQ rev (1m)15.79%
EPS NQ rev (3m)40%
EPS NY rev (1m)12.73%
EPS NY rev (3m)-5%
Revenue NQ rev (1m)3.52%
Revenue NQ rev (3m)18.01%
Revenue NY rev (1m)-0.75%
Revenue NY rev (3m)5.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.01
P/FCF N/A
P/OCF N/A
P/B 30.14
P/tB N/A
EV/EBITDA 65.95
EPS(TTM)-0.21
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0.71
BVpS0.09
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.61%
ROE -184.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.92%
FCFM N/A
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score3
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF N/A
Debt/EBITDA 4.55
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 2.02
Altman-Z -5.15
F-Score3
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
EPS Next Y48.07%
EPS Next 2Y41.42%
EPS Next 3Y36.46%
EPS Next 5Y52.37%
Revenue 1Y (TTM)-1.23%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%75.84%
Revenue Next Year26.41%
Revenue Next 2Y36.64%
Revenue Next 3Y32.75%
Revenue Next 5Y35.6%
EBIT growth 1Y47.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.6%
OCF growth 3YN/A
OCF growth 5YN/A